Premium
BLOOD‐SPOT 17α‐HYDROXYPROGESTERONE RADIOIMMUNOASSAY IN THE FOLLOW‐UP OF CONGENITAL ADRENAL HYPERPLASIA
Author(s) -
SÓLYOM J.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb02964.x
Subject(s) - congenital adrenal hyperplasia , radioimmunoassay , hydroxyprogesterone , endocrinology , medicine , blood sampling , dried blood spot , circadian rhythm , immunoassay , blood plasma , chemistry , chromatography , antibody , hormone , immunology , steroid
SUMMARY The value of plasma 17α‐hydroxyprogesterone (17α‐OHP) concentration in monitoring the treatment of congenital adrenal hyperplasia (CAH) was studied by using a capillary blood micromethod. The blood‐spot 17‐OHP radioim‐ munoassay method involves serial sampling throughout the day and sending the samples into a centre by mail. Follow‐up of seven children treated for CAH due to 21‐hydroxylase deficiency showed that a single measurement of plasma 17‐OHP concentration cannot be relied upon to determine adequacy of control, since circadian variation and timing of the sample in relation to the last dose of glucocorticoid may influence the plasma level of 17α‐OHP. Our data confirm the value of sequential 17α‐OHP assays throughout the day in the follow‐up of CAH. With the blood‐spot method the 17α‐OHP determinations can be used on a wide scale for monitoring therapy.